Effect of alendronate administration on bone mineral density and bone strength in castrated rats

Hormone and Metabolic Research

Volumn 37, Issue 7, 2005, Pages 414-418

  Broulik, P D ^a   Rosenkrancova J ^a   Ruzicka P ^a   Sedlacek R ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CZECH TECHNICAL UNIVERSITY IN PRAGUE   (Czech Republic)

Author keywords

Alendronate; Bone density; Bone strength; Castration

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PHOSPHATE;

ANIMAL TISSUE; ARTICLE; ASH; BONE DENSITY; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CASTRATION; CONTROLLED STUDY; DRUG MEGADOSE; MALE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; RAT;

ACID PHOSPHATASE; ALENDRONATE; ALKALINE PHOSPHATASE; ANIMALS; BIOMECHANICS; BODY WEIGHT; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CALCIUM; ISOENZYMES; MALE; ORCHIECTOMY; ORGAN SIZE; OSTEOCLASTS; RATS; SEMINAL VESICLES; TIBIA;

RATTUS NORVEGICUS;

EID: 23144467297     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-870234     Document Type: Article

References (27)

1. Fleisch H. Bisphosphonates: Mechanismus of action. Endocrine reviews 1998; 19: 80-100
2. Nevitt MG, Thompson DE, Black DM, Rubin SR, Eusund K, Yates AJ, Cummings SR. Effect of alendronate on limited days and bed disability days caused by back pain in postmenopausal women with existing vertebral fractures. Archives of Internal Medicine 2000; 160: 77-85
3. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28: 524-531
4. Frost HM, Jee WSS. On the rat model of human osteopenias and osteoporoses. Bone Miner 1992; 18: 227-1236
5. Mosekilde L. Assessing bone quality-animal models in preclinical osteoporosis research. Bone 1995; 17: 3435-3525
6. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner res 2000; 15: 183-187
7. Kalu DN, Hardin RR, Ceckerham R. Evaluation of the pathogenesis of skeletal changes in ovariectomized rats. Endocrinology 1994; 115: 507-511
8. Gitelman H. An improved automated procedure for the determination of calcium in biological specimens. Anal Biochem 1967; 18: 521-531
9. Kraml J. A semiautomated determination of phospholipids. Clin Chim Acta 1966; 13: 442-448
10. Štěpán JJ, Šilinková- Málková E, Havránek T, Formánková J, Zichová J, Lachmanová J, Traková M, Broulik P, Pacovský V. Relationship of plasma tartrate-resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperpathyrodism. Clin Chim Acta 1983; 133: 189-200
11. Moss D. A simplified heat-inactivation method for investigation alkaline phosphatase Isoenzymes in serum. Clin Chim Acta 1975; 61: 63-71
12. Beall PT, Misra LK, Young RL, Spjut HJ, Evans HJ, Le Blame A. Clomiphene protects against osteoporosis in the mature ovariectomized rat. Calcif Tissue Int 1984; 36: 123-125
13. Vanderschueren DE, Vautterck AMH, Suiker WJ, Wisser LPC, Schot R, Bouillon R. Bone and mineral metabolism in aged male rats. Short and long term effects of androgen deficiency. Endocrinology 1992; 130: 2906-2916
14. Turner CH, Burr DB. Basic biomechanical measurements of bone: A tutorial. Bone 1993; 14: 595-608
15. Růžička R, Michálek J, Rosenkrancová J, Sedláček R. Cross section parameters acquisition from digital images. Prague: Proc. Of workshop 2002. Prague CTU, 2002; B: 910-911
16. Duncan D. Multiple range and multiple F test. Biometrics 1955; 11: 1-4
17. Seeman E. Unresolved issues in osteoporosis in men. Rev in Endocrine and Metabolic Disorders 2001; 2: 45-64
18. Orwoll E, Ettinger M, Weiss S. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-610.
19. 1999; 14(suppl 1): S184 Abstract 1205
20. Burr DB, Forwood MR, Fyhrie DP, Martin RB, Schaffer MB, Turner CHH. Bone microdemage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res 1997; 12: 6-15
21. Ott SM. Fractures after long term alendronate therapy. J Clin Endocrinol Metab 2001; 86: 1835-1842
22. Laurutzen DB, Balena R, Shea M, Seedor JG, Markatos A, Le HM, Toolan BC, Myers ER, Rodan GA, Hayes WC. Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats. J Bone Miner Res 1993; 8: 871-879
23. Azuma Y, Oue Y, Kanatani H, Ohta T, Kiyoki M, Komoriya K. Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats. J Pharmacol Exp Ther 1998; 286: 128-135
24. Giavaresi G, Fini M, Gnudi S, Aldinin NN, Roca M, Carpi A, Giardino R. Comparison of calcitonin, alendronate and fluorophosphate effects on ovariectomized rat bone. Biomed Pharmacother 2001; 55: 397-403
25. Ito M, Azuma Y, Takagi H, Kamimura T, Komoriya K, Ohta T, Kawaguchi H. Preventive effects of sequential treatment with alendronate and in 1 alpha-hydroxyvitamin D3 on bone mass and strength in ovariectomized rats. Bone 2003; 33: 90-99
26. Huuskonen J, Arnala I, Olkkonen H, Alhava E. Alendronate influences bending force of femoral diaphysis after orchidectomy in rats. Ann Chir Gynaecol 2001; 90: 109-114
27. Wink CS, Felts WJL. Effects of castration on the bone structure of male rats. A model of osteoporosis. Calcif Tissue Int 1980; 32: 77-82